उत्पाद विवरण
Azalive 100 mg Injection is a targeted anticancer therapy specifically formulated for the treatment of myelodysplastic syndrome (MDS), a condition characterized by the production of dysfunctional blood cells in the bone marrow, resulting in insufficient healthy blood cell counts. This medication belongs to the demethylation agent class, functioning by blocking DNA methylation, a crucial process that can disrupt normal gene expression and lead to cellular abnormalities. By effectively halting this methylation, Azalive aids in restoring proper gene function, promoting the formation of healthy blood cells while simultaneously eliminating the harmful cells within the bone marrow. Patients receiving Azalive should be aware of potential side effects and consult their healthcare provider for guidance regarding its use, especially if they have pre-existing conditions or are taking other medications. This injection not only supports blood cell health but also plays a vital role in managing the complications associated with MDS. Azalive 100 mg is administered under professional supervision to ensure optimal efficacy and safety. For anyone navigating the challenges of myelodysplastic syndrome, Azalive represents a significant advancement in the pursuit of healthier blood cell production and overall well-being.Specialized Hospital AdministrationAzalive 100 mg Injection is designed for use exclusively in hospitals and healthcare facilities. The injection is processed and administered under the guidance of medical professionals, ensuring precise reconstitution and safe handling. Its controlled allocation supports advanced therapeutic requirements, making it suitable for distribution among healthcare providers and institutional suppliers.
Strict Prescription and Handling GuidelinesThis medication necessitates a valid prescription and is reconstituted right before use to maintain efficacy. Further, as each vial is intended for single use only, any remaining solution is safely discarded, reducing contamination risks. Such measures are established to uphold patient safety and medication integrity, particularly in high-demand hospital settings.
FAQ's of Azalive 100 mg Injection:
Q: How is Azalive 100 mg Injection administered?
A: Azalive 100 mg Injection is administered intravenously or subcutaneously by a qualified healthcare provider, typically in a hospital setting, following reconstitution of the powder with a compatible diluent.
Q: What is required before using Azalive 100 mg Injection?
A: Before use, the powder in the vial must be reconstituted according to medical guidelines. Only qualified healthcare professionals should carry out this process to ensure the injection's effectiveness and safety.
Q: When should Azalive 100 mg Injection be used?
A: Azalive 100 mg Injection should be used strictly under a doctor's recommendation in hospital environments, as part of prescribed treatment protocols for eligible patients.
Q: Where is this product manufactured and intended for use?
A: Azalive 100 mg Injection is manufactured in India by Sun Pharmaceutical and is strictly intended for hospital use, distributed to medical institutions, healthcare professionals, and related suppliers.
Q: What are the benefits of Azalive 100 mg Injection for hospitals and distributors?
A: This product offers reliable quality from a reputable Indian manufacturer, supports advanced hospital therapies, and is packaged for efficient distribution to clinics, medical distributors, exporters, suppliers, and wholesalers.
Q: Is Azalive 100 mg Injection intended for single use?
A: Yes, each vial is designed for single use only. After reconstitution and administration, any unused solution must be discarded to maintain safety standards.
Send Email 
जांच भेजें
जांच भेजें
एसएमएस भेजें
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese